The wide overlap in the survival range of grades 2 and 3 IDH-mutant glioma patients appears in part due to the subjective nature of the histological grading of IDH-mutant tumors: There are no sharp and objective criteria distinguishing grade 2 form grade 3 tumors. The gene discussed is IDH1; the disease is central nervous system cancer.